New assay aims to improve invasive breast cancer detection and treatment.
- PreludeDx's AiDaBreast assay receives FDA breakthrough status.
- The assay aims to assist in early invasive breast cancer detection.
- This designation could expedite the development and review process.
PreludeDx has announced that its AiDaBreast assay has received Breakthrough Device Designation from the FDA. This designation is intended for medical devices that offer significant advantages over existing options, particularly for challenging medical conditions. The AiDaBreast assay is designed to improve the detection and treatment of early-stage invasive breast cancer.
The AiDaBreast assay focuses on addressing the challenges associated with early-stage invasive breast cancer diagnosis and treatment. By receiving this designation, PreludeDx aims to expedite the development and regulatory review process for the assay. This could potentially lead to quicker access for patients who need more effective tools for breast cancer management.
The FDA's Breakthrough Device Designation is granted to devices that provide more effective treatment or diagnosis for serious conditions. With this support, PreludeDx is positioned to advance its AiDaBreast assay, enhancing options available for those battling early-stage invasive breast cancer.
